# Neuphoria Therapeutics Inc. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6 | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/neuphoria-therapeutics-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 18 | | Claims under review | 1 | | Evidence records | 5 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-18T07:13:33.900852+00:00 | | Last reviewed | 2026-10-18T07:13:33.900852+00:00 | ## Identity - Legal name: Neuphoria Therapeutics Inc. - Display name: Neuphoria Therapeutics Inc. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-18T11:20:32.663841+00:00 | | Completeness | 0.409 | | Record Quality | 0.833 | | Directors | 5 | | Committees | 4 | | Governance events | 11 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | PUBLISHED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Alan Fisher: Director. Status: current. Independent: true. Since: 2016-01-01. Committees: Audit (chair); Audit · Chair; Compensation (member); Compensation (member). claim_id=alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:5 - David Wilson: Director. Status: current. Independent: false. Since: 2016-01-01. claim_id=alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:6 - Jane Ryan: Director. Status: current. Independent: true. Since: 2020-01-01. Committees: Audit (member); Audit; Compensation · Chair (member); Compensation (chair). claim_id=alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:7 - Peter Miles Davies: Director. Status: current. Independent: true. Since: 2021-01-01. Committees: Audit (member). claim_id=alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:8 - Spyros Papapetropoulos: Director. Status: current. Independent: false. Since: 2023-01-01. claim_id=alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:9 ## Committees - Audit (audit). Chair: Alan Fisher. Members: Alan Fisher (chair, current); Jane Ryan (member, current); Peter Miles Davies (member, current). committee_id=alpha:committee:neuphoria-therapeutics-inc:audit - Audit · Chair; Compensation (audit). Chair: NOT_PUBLISHED. Members: Alan Fisher (member, current). committee_id=alpha:committee:neuphoria-therapeutics-inc:audit-chair-compensation - Audit; Compensation · Chair (audit). Chair: NOT_PUBLISHED. Members: Jane Ryan (member, current). committee_id=alpha:committee:neuphoria-therapeutics-inc:audit-compensation-chair - Compensation (compensation). Chair: Jane Ryan. Members: Jane Ryan (chair, current); Alan Fisher (member, current). committee_id=alpha:committee:neuphoria-therapeutics-inc:compensation ## Executive leadership - Spyros Papapetropoulos: President, Chief Executive Officer, and Director [CEO]. Status: current. claim_id=alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:10 - Tim Cunningham: Chief Financial Officer [CFO]. Status: current. claim_id=alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:11 ## Governance events - CEO_CHANGED: Spyros Papapetropoulos executive of Neuphoria Therapeutics Inc., effective 2025-09-29. Effective: 2025-09-29. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:1cr059b190wjp1 - CFO_CHANGED: Tim Cunningham executive of Neuphoria Therapeutics Inc., effective 2025-09-29. Effective: 2025-09-29. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:1jt2ixxaksmz5 - DIRECTOR_APPOINTED: Spyros Papapetropoulos seat on Neuphoria Therapeutics Inc., effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:1l8oypwsx5h4u - DIRECTOR_APPOINTED: Peter Miles Davies seat on Neuphoria Therapeutics Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:1b9s9lz1dswya5 - DIRECTOR_APPOINTED: Jane Ryan seat on Neuphoria Therapeutics Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:qb1djtn1irl7 - COMMITTEE_CREATED: Audit; Compensation · Chair committee of Neuphoria Therapeutics Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:c73sipmdvy37 - COMMITTEE_MEMBER_ADDED: Jane Ryan member of Audit; Compensation · Chair, effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:pg06tg1r6r4ea - DIRECTOR_APPOINTED: Alan Fisher seat on Neuphoria Therapeutics Inc., effective 2016-01-01. Effective: 2016-01-01. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:1ep85ww69x6r4 - DIRECTOR_APPOINTED: David Wilson seat on Neuphoria Therapeutics Inc., effective 2016-01-01. Effective: 2016-01-01. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:kepmczxnho3n - COMMITTEE_CREATED: Audit · Chair; Compensation committee of Neuphoria Therapeutics Inc., effective 2016-01-01. Effective: 2016-01-01. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:fdq6r4wna1mw - COMMITTEE_MEMBER_ADDED: Alan Fisher member of Audit · Chair; Compensation, effective 2016-01-01. Effective: 2016-01-01. Detected: 2026-10-18T07:13:33.900852+00:00. event_id=alpha:event:transition:f710irs374x1 ## Scoped resources - `alpha://company/neuphoria-therapeutics-inc` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record - `alpha://company/neuphoria-therapeutics-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=identity - `alpha://company/neuphoria-therapeutics-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=corporate-structure - `alpha://company/neuphoria-therapeutics-inc/board` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=board - `alpha://company/neuphoria-therapeutics-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=committees - `alpha://company/neuphoria-therapeutics-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=leadership - `alpha://company/neuphoria-therapeutics-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=ownership - `alpha://company/neuphoria-therapeutics-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=financials - `alpha://company/neuphoria-therapeutics-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=capital-structure - `alpha://company/neuphoria-therapeutics-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=compensation - `alpha://company/neuphoria-therapeutics-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=governance - `alpha://company/neuphoria-therapeutics-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=shareholder-governance - `alpha://company/neuphoria-therapeutics-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=audit - `alpha://company/neuphoria-therapeutics-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=legal - `alpha://company/neuphoria-therapeutics-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=risk - `alpha://company/neuphoria-therapeutics-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=cyber - `alpha://company/neuphoria-therapeutics-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=ai-governance - `alpha://company/neuphoria-therapeutics-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=agents - `alpha://company/neuphoria-therapeutics-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=ecosystem - `alpha://company/neuphoria-therapeutics-inc/events` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=events - `alpha://company/neuphoria-therapeutics-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=relationships - `alpha://company/neuphoria-therapeutics-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=assessments - `alpha://company/neuphoria-therapeutics-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - Claim alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_appointment:13: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"chair","person":{"alpha_id":"alpha:person:alan-fisher","name":"Alan Fisher"},"source_id":"board_seats"}` - Claim alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_appointment:14: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"member","person":{"alpha_id":"alpha:person:jane-ryan","name":"Jane Ryan"},"source_id":"board_seats"}` - Claim alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_appointment:15: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"member","person":{"alpha_id":"alpha:person:peter-miles-davies","name":"Peter Miles Davies"},"source_id":"board_seats"}` - Claim alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_appointment:17: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"chair","person":{"alpha_id":"alpha:person:jane-ryan","name":"Jane Ryan"},"source_id":"board_seats"}` - Claim alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_appointment:18: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"member","person":{"alpha_id":"alpha:person:alan-fisher","name":"Alan Fisher"},"source_id":"board_seats"}` ## Leadership - Alan Fisher: Director, Audit · Chair; Compensation. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:5. Valid from: 2016-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7. - David Wilson: Director. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:6. Valid from: 2016-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7. - Jane Ryan: Director, Audit; Compensation · Chair. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:7. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7. - Peter Miles Davies: Director, Audit. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:8. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7. - Spyros Papapetropoulos: Director. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:9. Valid from: 2023-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7. - Spyros Papapetropoulos: President, Chief Executive Officer, and Director. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:10. Valid from: 2025-09-29. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:409d3f30709b506cc42ba0ed090ce6ae1155611cff4c6d6b47304b60ad58496a. - Tim Cunningham: Chief Financial Officer. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:11. Valid from: 2025-09-29. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:74ead60348041b00b6efe6e68d5e31566f0bc11c24272cfaece8eded56371478. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - Audit: Chair Alan Fisher; Members Alan Fisher (Chair); Jane Ryan; Peter Miles Davies. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_record:12. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:164cdf7b8a7d957b3d761a45f876903c859ed58aa0956901c4689e4962f58c08. - Compensation: Chair Jane Ryan; Members Jane Ryan (Chair); Alan Fisher. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_record:16. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:164cdf7b8a7d957b3d761a45f876903c859ed58aa0956901c4689e4962f58c08. ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - Neuphoria Therapeutics Inc.. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:9defd8ac6fb79cb2cd35ee61bc160296f3a937a69d85b1bf1d4a7431e01cc0ca. ## Entity Status - Public listing published. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:9defd8ac6fb79cb2cd35ee61bc160296f3a937a69d85b1bf1d4a7431e01cc0ca. ## Published Fact - US. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:9defd8ac6fb79cb2cd35ee61bc160296f3a937a69d85b1bf1d4a7431e01cc0ca. ## Committee Appointment - Alan Fisher: chair, Audit. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_appointment:13. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:164cdf7b8a7d957b3d761a45f876903c859ed58aa0956901c4689e4962f58c08. - Jane Ryan: member, Audit. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_appointment:14. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:164cdf7b8a7d957b3d761a45f876903c859ed58aa0956901c4689e4962f58c08. - Peter Miles Davies: member, Audit. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_appointment:15. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:164cdf7b8a7d957b3d761a45f876903c859ed58aa0956901c4689e4962f58c08. - Jane Ryan: chair, Compensation. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_appointment:17. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:164cdf7b8a7d957b3d761a45f876903c859ed58aa0956901c4689e4962f58c08. - Alan Fisher: member, Compensation. Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:committee_appointment:18. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:164cdf7b8a7d957b3d761a45f876903c859ed58aa0956901c4689e4962f58c08. ## Security Listing - NEUP (NASDAQ). Claim: alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:security_listing:19. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:9defd8ac6fb79cb2cd35ee61bc160296f3a937a69d85b1bf1d4a7431e01cc0ca. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:9defd8ac6fb79cb2cd35ee61bc160296f3a937a69d85b1bf1d4a7431e01cc0ca: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/neuphoria-therapeutics-inc). - alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7: [Neuphoria Therapeutics Inc. DEF 14A 2025-10-30](https://www.sec.gov/Archives/edgar/data/1191070/000114036125039748/ny20055722x1_def14a.htm). - alpha:projection-evidence:document:409d3f30709b506cc42ba0ed090ce6ae1155611cff4c6d6b47304b60ad58496a: [NEUP 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1191070/000119312525223338/neup-20250630.htm). - alpha:projection-evidence:document:74ead60348041b00b6efe6e68d5e31566f0bc11c24272cfaece8eded56371478: [NEUP 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1191070/000119312525223338/neup-20250630.htm). - alpha:projection-evidence:164cdf7b8a7d957b3d761a45f876903c859ed58aa0956901c4689e4962f58c08: [Audit](https://www.sec.gov/Archives/edgar/data/1191070/000114036125039748/ny20055722x1_def14a.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/neuphoria-therapeutics-inc) - [Public Markdown](https://registry.alpha.ac/companies/neuphoria-therapeutics-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=jsonld) - MCP resource: `alpha://companies/neuphoria-therapeutics-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-18T11:20:32.471506+00:00; recorded 2026-10-18T11:20:32.471506+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.